XML 65 R52.htm IDEA: XBRL DOCUMENT v3.20.2
License agreements - Lilly (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 127 Months Ended
May 31, 2019
Mar. 31, 2016
Dec. 31, 2009
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
License agreements                
Research and Development Expense       $ 286,601 $ 289,363 $ 1,371,888 $ 559,908  
Revenues       688,043 529,932 1,256,550 1,027,789  
Product royalty revenues                
License agreements                
Revenues       92,753 76,035 $ 174,533 137,643  
Eli Lilly                
License agreements                
Upfront payment received under license agreement     $ 90,000          
Eli Lilly | Phase IIB                
License agreements                
Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop (as a percentage)           30.00%    
Associated future royalty payments from the initiation of a Phase IIb trial, if elected to not co-develop, percentage           20.00%    
Eli Lilly | Pre-specified Events | Maximum                
License agreements                
Upfront and immediate milestone payment to be received under license agreement     665,000          
Eli Lilly | Development Milestones                
License agreements                
Amount recognized and received for the achievement of a predefined milestone               $ 149,000
Eli Lilly | Development Milestones | Maximum                
License agreements                
Upfront and immediate milestone payment to be received under license agreement     150,000          
Eli Lilly | Regulatory Milestones                
License agreements                
Amount recognized and received for the achievement of a predefined milestone               $ 235,000
Eli Lilly | Regulatory Milestones | Maximum                
License agreements                
Upfront and immediate milestone payment to be received under license agreement     365,000          
Eli Lilly | Sales and Commercial Milestones | Maximum                
License agreements                
Upfront and immediate milestone payment to be received under license agreement     $ 150,000          
Eli Lilly | Product royalty revenues                
License agreements                
Revenues       25,800 19,100 $ 51,300 35,200  
Eli Lilly | GVHD                
License agreements                
Upfront payment under license agreement   $ 35,000            
Additional milestone payments under the license agreement   $ 40,000            
Eli Lilly | GVHD | Regulatory Milestones                
License agreements                
Milestone payment made under license agreement $ 20,000              
Eli Lilly | Milestone revenues                
License agreements                
Revenues       $ 0 $ 0 $ 0 $ 0